Sling Therapeutics Appoints Andrew Guggenhime to its Board of Directors [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
small molecule for the treatment of thyroid eye disease (TED), today announced the appointment of Andrew Guggenhime , an experienced biopharma executive, to its Board of Directors. "Andrew is a distinguished and highly respected leader in the biotech industry, and we are pleased to welcome him to our Board of Directors. He brings unparalleled operational, strategic and financial experience, all of which will be critical as we continue to gain momentum and advance our clinical programs," said Ryan Zeidan , Ph.D., President and CEO of Sling. "We look forward to benefitting from his contributions as we further bolster our efforts in anticipation of key milestones with our lead candidate, linsitinib, which is currently in a Phase 2b clinical trial and has the potential to be the first oral treatment for thyroid eye disease." "I am delighted to extend a warm welcome to Andrew as he joins Sling at such an exciting moment in our journey," said Faheem Hasnain, Chairman of the Board. "Andr
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- How Vaxcyte's Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors [Yahoo! Finance]Yahoo! Finance
- Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price [Yahoo! Finance]Yahoo! Finance
- Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in AdultsGlobeNewswire
- Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound [Yahoo! Finance]Yahoo! Finance
PCVX
Earnings
- 11/4/25 - Miss
PCVX
Sec Filings
- 12/19/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- PCVX's page on the SEC website